NASDAQ:GERN Geron (GERN) Stock Price, News & Analysis → Tech GIANT’s Plans to Revolutionize Crypto… (From Crypto 101 Media) (Ad) Free GERN Stock Alerts $3.81 -0.06 (-1.55%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$3.78▼$3.9050-Day Range$1.75▼$4.1452-Week Range$1.64▼$4.30Volume8.90 million shsAverage Volume11.16 million shsMarket Capitalization$2.26 billionP/E RatioN/ADividend YieldN/APrice Target$6.10 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Geron alerts: Email Address Geron MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside60.1% Upside$6.10 Price TargetShort InterestBearish8.33% of Shares Sold ShortDividend StrengthN/ASustainability-2.80Upright™ Environmental ScoreNews Sentiment0.43Based on 24 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.33) to ($0.14) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.62 out of 5 starsMedical Sector254th out of 905 stocksPharmaceutical Preparations Industry111th out of 422 stocks 4.4 Analyst's Opinion Consensus RatingGeron has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageGeron has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Geron's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.33% of the outstanding shares of Geron have been sold short.Short Interest Ratio / Days to CoverGeron has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Geron has recently increased by 5.92%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGeron does not currently pay a dividend.Dividend GrowthGeron does not have a long track record of dividend growth. Previous Next 1.3 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreGeron has received a -35.24% net impact score from Upright. The largest negative impact of Geron in category "GHG emissions" is driven by its "Nonwoven fabric machines" and "Textile spinning machines" products. See details.Environmental SustainabilityThe Environmental Impact score for Geron is -2.80. Previous Next 1.9 News and Social Media Coverage News SentimentGeron has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 24 news articles for Geron this week, compared to 4 articles on an average week.Search InterestOnly 35 people have searched for GERN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 22 people have added Geron to their MarketBeat watchlist in the last 30 days. This is a decrease of -8% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Geron insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.00% of the stock of Geron is held by insiders.Percentage Held by Institutions73.71% of the stock of Geron is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Geron's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Geron are expected to grow in the coming year, from ($0.33) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Geron is -10.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Geron is -10.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGeron has a P/B Ratio of 8.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Geron's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBREAKING – Pentagon to Spend $20 Billion on “Distributed AI”BREAKING - Pentagon to Spend $20 Billion on "Distributed AI" The U.S. Space Force calls it a "game changer." And one tiny firm is poised to win the contract to build it.Discover the name and ticker of this $2 stock here >>> About Geron Stock (NASDAQ:GERN)Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.Read More GERN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GERN Stock News HeadlinesMay 6, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Stock Rating Reaffirmed by Needham & Company LLCMay 6, 2024 | americanbankingnews.comGeron Co. Expected to Earn Q4 2025 Earnings of ($0.01) Per Share (NASDAQ:GERN)May 8, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 3, 2024 | finance.yahoo.comGeron Corporation (NASDAQ:GERN) Q1 2024 Earnings Call TranscriptMay 3, 2024 | markets.businessinsider.comBuy Rating Affirmed: Anticipating Imetelstat’s Approval and Market PotentialMay 3, 2024 | finance.yahoo.comGeron Corp (GERN) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves and Financial HealthMay 3, 2024 | finance.yahoo.comThis Is Why Geron Corporation's (NASDAQ:GERN) CEO Compensation Looks AppropriateMay 3, 2024 | finance.yahoo.comQ1 2024 Geron Corp Earnings CallMay 8, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.May 3, 2024 | fool.comGeron (GERN) Q1 2024 Earnings Call TranscriptMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Geron Amid Positive Imetelstat Launch Prospects and Strong FinancialsMay 2, 2024 | markets.businessinsider.comGeron Corporation Q1 Loss increases, but beats estimatesMay 2, 2024 | investorplace.comGERN Stock Earnings: Geron Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | finance.yahoo.comEx-day dividend payment of AB Rokiškio sūrisMay 2, 2024 | businesswire.comGeron Corporation Reports First Quarter 2024 Financial Results and Business HighlightsMay 2, 2024 | investorplace.comThe Top 3 Penny Stocks to Buy in April 2024May 2, 2024 | americanbankingnews.comGeron Co. (NASDAQ:GERN) Short Interest Up 5.9% in AprilMay 1, 2024 | seekingalpha.comGeron: FDA PDUFA Review With Continued Imetelstat AdvancementMay 1, 2024 | msn.comBaird Downgrades Geron (GERN)May 1, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Downgraded by Robert W. Baird to NeutralApril 30, 2024 | msn.comBaird downgrades Geron to neutral, cites valuation concernsApril 30, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Dyne Therapeutics (DYN) and Geron (GERN)April 30, 2024 | msn.comTD Cowen Initiates Coverage of Geron (GERN) with Buy RecommendationApril 30, 2024 | americanbankingnews.comGeron (NASDAQ:GERN) Receives New Coverage from Analysts at TD CowenApril 29, 2024 | msn.comTD Cowen starts Geron at buy, cites imetelstat market potentialApril 29, 2024 | benzinga.comNavigating 10 Analyst Ratings For GeronApril 25, 2024 | businesswire.comGeron to Announce First Quarter 2024 Financial Results on May 2, 2024See More Headlines Receive GERN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Geron and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today5/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:GERN CUSIP37416310 CIK886744 Webwww.geron.com Phone(650) 473-7700Fax650-473-7750Employees141Year FoundedN/APrice Target and Rating Average Stock Price Target$6.10 High Stock Price Target$10.00 Low Stock Price Target$4.50 Potential Upside/Downside+57.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,130,000.00 Net Margins-38,730.00% Pretax Margin-38,729.81% Return on Equity-68.16% Return on Assets-47.26% Debt Debt-to-Equity Ratio0.03 Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual Sales$240,000.00 Price / Sales9,564.22 Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book8.41Miscellaneous Outstanding Shares593,130,000Free Float575,339,000Market Cap$2.30 billion OptionableOptionable Beta0.55 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. John A. Scarlett M.D. (Age 73)Chairman of the Board, President & CEO Comp: $1.36MMs. Michelle J. Robertson (Age 57)Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Comp: $340.98kDr. Andrew J. Grethlein Ph.D. (Age 60)Executive VP & COO Comp: $827.01kMr. Scott SamuelsExecutive VP, Chief Legal Officer & Corporate SecretaryMs. Aron FeingoldVice President of Investor Relations & Corporate CommunicationsMs. Shannon Odam (Age 49)Senior VP & Chief People Officer Ms. Melissa A. Kelly Behrs (Age 60)Executive VP of Business Operations & Chief Alliance Officer Comp: $753.22kMr. Anil Kapur (Age 54)Executive VP of Corporate Strategy & Chief Commercial Officer Comp: $654.89kMr. Edward E. Koval (Age 62)Executive VP & Chief Business Officer Dr. Faye Feller M.D. (Age 41)Executive VP & Chief Medical Officer More ExecutivesKey CompetitorsChinook TherapeuticsNASDAQ:KDNYDynavax TechnologiesNASDAQ:DVAXAmicus TherapeuticsNASDAQ:FOLDLigand PharmaceuticalsNASDAQ:LGNDIronwood PharmaceuticalsNASDAQ:IRWDView All CompetitorsInsiders & InstitutionsRussell Investments Group Ltd.Bought 513,365 shares on 5/8/2024Ownership: 0.295%ProShare Advisors LLCBought 10,813 shares on 5/8/2024Ownership: 0.022%Inspire Investing LLCSold 73,450 shares on 5/8/2024Ownership: 0.018%Swiss National BankBought 30,700 shares on 5/7/2024Ownership: 0.136%SG Americas Securities LLCSold 138,997 shares on 5/7/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions GERN Stock Analysis - Frequently Asked Questions Should I buy or sell Geron stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GERN shares. View GERN analyst ratings or view top-rated stocks. What is Geron's stock price target for 2024? 5 brokers have issued twelve-month price objectives for Geron's stock. Their GERN share price targets range from $4.50 to $10.00. On average, they predict the company's share price to reach $6.10 in the next year. This suggests a possible upside of 60.1% from the stock's current price. View analysts price targets for GERN or view top-rated stocks among Wall Street analysts. How have GERN shares performed in 2024? Geron's stock was trading at $2.11 on January 1st, 2024. Since then, GERN stock has increased by 80.6% and is now trading at $3.81. View the best growth stocks for 2024 here. Are investors shorting Geron? Geron saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 49,420,000 shares, an increase of 5.9% from the March 31st total of 46,660,000 shares. Based on an average daily trading volume, of 12,430,000 shares, the short-interest ratio is currently 4.0 days. View Geron's Short Interest. When is Geron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our GERN earnings forecast. How were Geron's earnings last quarter? Geron Co. (NASDAQ:GERN) released its earnings results on Wednesday, February, 28th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.01. The biopharmaceutical company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. Geron had a negative trailing twelve-month return on equity of 68.16% and a negative net margin of 38,730.00%. The business's revenue for the quarter was down 77.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.10) EPS. What ETFs hold Geron's stock? ETFs with the largest weight of Geron (NASDAQ:GERN) stock in their portfolio include Invesco Pharmaceuticals ETF (PJP), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), iShares Genomics Immunology and Healthcare ETF (IDNA), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI). What is John A. Scarlett's approval rating as Geron's CEO? 5 employees have rated Geron Chief Executive Officer John A. Scarlett on Glassdoor.com. John A. Scarlett has an approval rating of 82% among the company's employees. What other stocks do shareholders of Geron own? Based on aggregate information from My MarketBeat watchlists, some companies that other Geron investors own include Novavax (NVAX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Rigel Pharmaceuticals (RIGL), Chesapeake Energy (CHKAQ), Organigram (OGI), SCYNEXIS (SCYX) and Bionano Genomics (BNGO). Who are Geron's major shareholders? Geron's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vivo Capital LLC (4.98%), Russell Investments Group Ltd. (0.30%), Swiss National Bank (0.14%), Allspring Global Investments Holdings LLC (0.06%), BNP Paribas Financial Markets (0.05%) and Commonwealth Equity Services LLC (0.05%). Insiders that own company stock include Andrew J Grethlein, Elizabeth G O'farrell, John A Scarlett, Olivia Kyusuk Bloom, Susan Molineaux and V Bryan Lawlis. View institutional ownership trends. How do I buy shares of Geron? Shares of GERN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GERN) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyAI “wealth window” is closing June 25thParadigm PressGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
